Literature DB >> 799469

Immunological aspects of hepatitis B virus infection.

T S Edgington, F V Chisari.   

Abstract

Infection of man and chimpanzees with the hepatitis B virus (HBV) is associated with diffuse hepatocellular infection and variable manifestations of disease which may not only reflect the character of the host immune response, but also depend upon differences in the cellular biology of this minimally cytopathic or noncytopathic agent. The presence of hepatocellular injury and the course of disease do not appear to be related to the presence of viral antigens in hepatocytes or to the specific pattern of genome expression. HBV infection is typically associated with both humoral and cellular immune responses to viral and hepatocellular antigens. Whereas cellular effector systems may be responsible for immunologically mediated hepatocellular injury, the patterns of viral antigen synthesis and expression may be modulated by the humoral immune response. Aberration of lymphocyte function occurs during acute hepatitis type B. Thymus-derived lymphocyte function is abnormal and is associated with persistent humoral suppression of T lymphocyte function during the development of the chronic carrier state. Extrahepatic disease appears attributable to the formation and deposition of HBS Ag-antibody complexes. Current information of the biology and immunology of HBV and other viruses has been integrated into a hypothesis to explain the pathogenesis of injury and events associated with persistent infection. Hepatocellular injury and persistence of viral synthesis may be determined by the regulation of synthesis and hepatocyte surface expression of viral and cellular antigens as well as by the specificity and character of the host immune response. Termination of HBV infection is viewed as suppression of viral genome rather than eradication of infected cells.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 799469

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  27 in total

Review 1.  Thymomodulin: biological properties and clinical applications.

Authors:  N M Kouttab; M Prada; P Cazzola
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

2.  Variations in codons 84-101 in the core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis B virus infection.

Authors:  T Ehata; M Omata; O Yokosuka; K Hosoda; M Ohto
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

3.  In vitro morphological studies on antibody-dependent nonimmune lymphocyte-mediated cytotoxicity in chronic active liver disease.

Authors:  H Kawanishi
Journal:  Am J Dig Dis       Date:  1978-02

Review 4.  Pathologic aspects of cirrhosis. A review.

Authors:  H Popper
Journal:  Am J Pathol       Date:  1977-04       Impact factor: 4.307

5.  K-lymphocytes (killer-cells) in Crohn's disease and acute virus B-hepatitis.

Authors:  R Eckhardt; P Kloos; M P Dierich; K H Meyer zum Büschenfelde
Journal:  Gut       Date:  1977-12       Impact factor: 23.059

6.  Viral replication in chronic hepatitis B virus infection.

Authors:  B W Trotman
Journal:  Dig Dis Sci       Date:  1983-11       Impact factor: 3.199

7.  Two distinct types of hepatitis in experimental hepatitis B virus infection.

Authors:  T Shikata; T Karasawa; K Abe
Journal:  Am J Pathol       Date:  1980-05       Impact factor: 4.307

8.  Immunopathologic aspects of woodchuck hepatitis.

Authors:  D Frommel; D Crevat; L Vitvitsky; C Pichoud; O Hantz; M Chevalier; J A Grimaud; J Lindberg; C G Trépo
Journal:  Am J Pathol       Date:  1984-04       Impact factor: 4.307

9.  Effects of interferon and adenine arabinoside treatment of hepatitis B virus infection on cellular immune responses.

Authors:  B Hafkin; R B Pollard; M L Tiku; W S Robinson; T C Merigan
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

10.  Hepatocyte turnover during resolution of a transient hepadnaviral infection.

Authors:  Jesse Summers; Allison R Jilbert; Wengang Yang; Carol E Aldrich; Jeffry Saputelli; Samuel Litwin; Eugene Toll; William S Mason
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.